• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$4.04 -$0.01 (-0.25%)

REAL-TIME: Last trade at

Corcept Therapeutics, Inc.

NASDAQ:CORT

Corcept Therapeutics anticipates cash balance sufficient to fund co through 2013

Corcept Therapeutics reports Q1 EPS (13c), consensus (11c)

Corcept Therapeutics: Korlym Is Available Now

The Funded: Corcept Therapeutics, NComputing

The Funded: NComputing, Corcept Therapeutics

Corcept Therapeutics announces national product launch of Korlym

Corcept Therapeutics Announces National Product Launch of Korlym(TM) for Patients With Endogenous Cushing's Syndrome

Corcept says phase 3 SEISMIC trial showed significant improvement

UPDATE: Data Published in Premier Endocrinology Journal Shows Korlym(TM) Provides Significant Clinical Improvement in Patients With Endogenous Cushing's Syndrome

Piper Jaffray's biotech and specialty pharma analysts hold a conference call

Small is the New Big

Oppenheimer Reiterates Corcept Therapeutics (CORT) As 'Outperform', $9 PT

Akela's PharmaForm to manufacture Corcept's Korlym

PharmaForm announces commercial manufacturing contract for Corcept's Korlym™

Biotech Stocks With Bullish Trends From Short Sellers (ARIA, AVEO, CORT, MDVN)

Corcept Therapeutics Announces Exercise of Warrants and Private Placement of New Warrants

Company news: Corcept Therapeutics and Daiichi Sankyo

Corcept Therapeutics pricing for Korlym higher than expected, says Leerink

Korlym(TM) (mifepristone), the First Approved Medication for Patients With Endogenous Cushing's Syndrome, to Be Available by April 11

Corcept Therapeutics - Proud of Corcept’s transfor..

Corcept Therapeutics reports Q4 EPS (12c), consensus (9c)

Corcept Therapeutics Announces Fourth Quarter Results and Corporate and Development Update

One-on-One with CEO Joe Belanoff of Corcept Therapeutics

Corcept Therapeutics: Is There More To Come?

Top Stock Alerts for Day Traders: Genworth Financial, RadioShack, Corcept Therapeutics, MGIC Investment, and DryShips

Corcept Therapeutics (CORT) Surged To Nearly An 8-Month High After FDA Approval

Company news: Bristol-Myers Squibb, Corcept Therapeutics, Vivus, Orexigen and Arena

24/7 Wall St. Closing Bell (ORCL, ITRI, CSX, ABB, GILD, BKS, BYD, CCO, CIE, DTG, HL, JAKK, M, MDT, PXD, SKS, WLK, THLD, CORT, GTXI, CHTP, WMT, WFT)

The Bulls Are Back! Corcept Therapeutics Inc. (CORT), Threshold Pharmaceuticals Inc. (THLD), Gulf Resources Inc. (GURE)

Mid-day Movers (THLD, CORT, GURE, GTXI, WFT)

Corcept Therapeutics rises 45.2%

Corcept Therapeutics rises 56.4%

Corcept Therapeutics target raised to $9 from $7 at Stifel Nicolaus

Corcept Therapeutics rises 62.7%

Corcept Therapeutics to host sales conference call

Corcept's Korlym approved by FDA for Cushing's syndrome

Corcept Therapeutics Incorporated Announces FDA Approval of Korlym(TM) (Mifepristone): First and Only Approved Medication for Cushing's Syndrome Patients

Corcept Therapeutics trading halted, news pending

Biotech Stock Mailbag: Corcept Therapeutics, Reader Retorts

Corcept Therapeutics rises 6%

See More Articles...